Patent application number | Description | Published |
20080287447 | Methods for preparing eszopiclone - Methods for the preparation of crystalline eszopiclone free base in water, in the absence of organic solvents, are provided. The methods are more environmentally acceptable than prior art methods, and produce eszopiclone free base essentially free of residual organic solvent. | 11-20-2008 |
20080300409 | Crystalline clopidogrel hydrobromide and processes for preparation thereof - Provided are crystalline forms of clopidogrel hydrobromide and processes for their preparation. | 12-04-2008 |
20080306268 | Crystalline clopidogrel hydrobromide and processes for preparation thereof - Provided are crystalline forms of clopidogrel hydrobromide and processes for their preparation. | 12-11-2008 |
20090018336 | Racemization process of R-zopiclone - In one of the embodiments, the present invention provides a racemization process comprising: removing the organic solvent from a mother liquor comprising R-zopiclone malate, eszopiclone malate and an organic solvent to obtain a mixture of R-zopiclone malate and eszopiclone malate; mixing the mixture with water to obtain a solution; neutralizing R-zopiclone malate and eszopiclone malate in the solution to obtain a precipitate of R-zopiclone and eszopiclone; filtering the precipitate; mixing the precipitate of R-zopiclone and eszopiclone with DBU and an organic inert solvent having a boiling point of at least 80° C.; heating; and cooling to obtain a zopiclone racemate. | 01-15-2009 |
20090187022 | Crystalline clopidogrel hydrobromide and processes for preparation thereof - Provided are crystalline forms of clopidogrel hydrobromide and processes for their preparation. | 07-23-2009 |
20090188305 | Reference standard for characterization of rosuvastatin - Provided are rosuvastatin degradation products and their use as a reference standard (including reference marker) for analysis of rosuvastatin. | 07-30-2009 |
20100000302 | Process for preparing forms of atorvastatin calcium substantially free of impurities - The preparation of atorvastatin calcium epoxide dihydroxy (AED) is described. AED can be used as a standard or marker in determining the amount of AED in a sample. AED can therefore be used as a tool in preparing atorvastatin calcium substantially free of AED. | 01-07-2010 |
20100029774 | ALISKIREN MONOFUMARATE AND PROCESSES FOR PREPARATION THEREOF - The present invention provides a novel fumarate compound of aliskiren monofumarate, and process for preparation thereof. The present invention also provides pharmaceutical compositions comprising aliskiren monofumarate, and methods of using aliskiren monofumarate for treating hypertension. | 02-04-2010 |
20100029943 | METHODS FOR PREPARING ESZOPICLONE CRYSTALLINE FORM A, SUBSTANTIALLY PURE ESZOPICLONE AND OPTICALLY ENRICHED ESZOPICLONE - The present invention provides methods for preparing eszopiclone Form A, substantially chemically pure eszopiclone, or eszopiclone with low level(s) of residual solvent(s). The present invention also provides eszopiclone with low level(s) of residual solvent(s). The present invention also provides a process for optical enrichment of eszopiclone free base. For instance, one of the embodiments of the invention is directed to a method of preparing eszopiclone Form A, wherein the method comprises crystallizing eszopiclone free base from a solvent selected from the group consisting of isopropanol (IPA), methyl isobutyl ketone (MIBK), acetone, n-butanol, i-butanolisobutanol, 2-butanol, tetrahydrofuran (THF), dimethyl carbonate, methanol, ethanol, ethyl lactate, dimethylformamide (DMF), carbon tetrachloride, toluene, iso-butyl acetate and mixtures thereof. | 02-04-2010 |
20100041885 | CRYSTALLINE FORMS OF SITAGLIPTIN PHOSPHATE - A Sitagliptin phosphate characterized by data selected from the group consisting of: a powder XRD pattern with peaks at 4.7, 13.5, 17.7, 18.3, and 23.7±0.2 degrees two theta; a powder XRD pattern with peaks at about 4.7, 13.5, and 15.5±0.2 degrees two theta and at least another two peaks selected from the following list: 14.0, 14.4, 18.3, 19.2, 19.5 and 23.7±0.2 degrees two theta; and a powder XRD pattern with peaks at about 13.5, 19.2, and 19.5±0.2 degrees two theta and at least another two peaks selected from the following list: 4.7, 14.0, 15.1, 15.5, 18.3, and 18.7±0.2 degrees two theta; a powder XRD pattern with peaks at about 13.5, 15.5, 19.2, 23.7, and 24.4±0.2 degrees two theta; and a powder XRD pattern with peaks at about 4.65, 13.46, 17.63, 18.30, and 23.66±0.10 degrees two theta, processes for preparing said Sitagliptin crystalline form, and pharmaceutical compositions thereof, are provided. | 02-18-2010 |
20100197793 | SOLID STATE FORMS OF ALISKIREN COMPOUNDS - The invention relates to solid states of pharmaceutically acceptable compounds of aliskiren, and processes for preparation thereof. The invention further provides pharmaceutical formulations comprising the amorphous or crystalline forms of pharmaceutically acceptable compounds of aliskiren and processes thereof; and a method of inhibiting renin for treating hypertension. | 08-05-2010 |
20120029083 | POLYMORPHIC FORMS OF ALISKIREN HEMIFUMARATE AND PROCESS FOR PREPARATION THEREOF - Provided are amorphous and polymorphic forms of aliskiren hemifumarate, pharmaceutical compositions thereof, and processes for their preparation. | 02-02-2012 |
20120095264 | SOLID STATES OF ALISKIREN FREE BASE - The present invention describes a solid state of aliskiren free base, and process for the preparation thereof. | 04-19-2012 |